RxDoctor Payments DataLook up a doctor →

James Isernia, MD

Internal Medicine · Myrtle Beach, SCNPI 1144281148

Payments from drug & device makers

$68,619in general payments, 2019–2025

Across 803 payments — averaging $85.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$47K
  • AstraZeneca$6K
  • Amgen$5K
  • AbbVie$1K
  • Novo Nordisk$1K
  • UCB, Inc.$792
  • plus $7K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alnylam Pharmaceuticals Inc.21$46,832
AstraZeneca(2 entities)38$6,218
Amgen(2 entities)84$5,497
AbbVie(2 entities)103$1,233
Novo Nordisk68$1,157
UCB, Inc.44$792
Johnson & Johnson(3 entities)47$676
Sanofi-aventis U.S. LLC36$603
Pfizer47$522
Lilly USA, LLC24$365
Boehringer Ingelheim18$345
Sunovion Pharmaceuticals Inc.17$299
Merck20$278
Amarin Pharma, Inc.16$260
Novartis16$256
Radius Health, Inc.13$229
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC22$223
GSK24$196
E.r. Squibb & Sons, L.L.C.11$178
Takeda Pharmaceuticals U.S.A., Inc.14$146
Averitas Pharma Inc.5$146
Xeris Pharmaceuticals, Inc.8$143
Aurinia Pharma U.S., Inc.6$125
BETA Bionics, Inc.4$125
Bayer7$118
Otsuka America Pharmaceutical, Inc.5$103
Avanir Pharmaceuticals, Inc.7$100
Astellas Pharma US Inc6$98
Abbott5$95
Esperion Therapeutics, Inc.4$94
Daiichi Sankyo Inc.5$94
Calliditas Therapeutics US Inc.4$92
Kyowa Kirin, Inc.4$87
Biogen5$87
Mallinckrodt Hospital Products Inc.3$76
Currax Pharmaceuticals LLC5$69
Mannkind Corporation3$46
Madrigal Pharmaceuticals1$44
Biohaven Pharmaceuticals, Inc.2$44
Kowa Pharmaceuticals America, Inc.3$41
Shire North American Group Inc2$40
Aimmune Therapeutics, Inc.2$40
Corcept Therapeutics2$40
Mylan Specialty L.p.2$39
Philips North America LLC2$37
Eisai Inc.2$36
Genentech USA, Inc.2$33
Sumitomo Pharma America, Inc.1$27
Vital Connect, Inc1$23
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$19
Nestle Healthcare Nutrition Inc.1$17
Fresenius Kabi USA, LLC1$17
Scilex Pharmaceuticals Inc.1$16
Dexcom, Inc.1$16
Halozyme Inc1$15
Boston Scientific1$14
Upsher-smith Laboratories LLC1$13
Biodelivery Sciences International, Inc.1$13
Ironwood Pharmaceuticals, Inc1$13
Cequr Corporation1$12

How this compares

$68,619 in reported general payments places this provider in the 95th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina →

Medicare billing

Part B allowed, 2024
$480,187
Medicare patients
826
Services billed
19,975

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Myrtle Beach

See the full list for South Carolina →

Where these figures come from

Is this you, or does something look wrong? →